Filtered By:
Drug: Docetaxel

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 178 results found since Jan 2013.

Hypoxia-induced STAT3 Contributes to Chemoresistance and Epithelial-Mesenchymal Transition in Prostate Cancer Cells.
This study suggests a new rationale for inhibiting cancer chemoresistance and EMT under hypoxia using anti-STAT3 strategies. PMID: 25701777 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - February 18, 2015 Category: Biochemistry Authors: Liu ZQ, Han YC, Fang JM, Hu F, Zhang X, Xu Q Tags: Biochem Biophys Res Commun Source Type: research

RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel.
In conclusion, our study demonstrates RASSF10 is frequently methylated in human colorectal cancer leading to loss of expression. RASSF10 normally suppresses human colorectal cancer growth by activating P53 signaling in colorectal cancer, and restored expression sensitizes colorectal cancer to docetaxel. PMID: 25638156 [PubMed - as supplied by publisher]
Source: Oncotarget - February 6, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Abstract 2623: PI3K/mTOR dual inhibitor PF-5212384 inhibits aberrant NF-kB activation and exhibits activity in combination with MEK inhibitor PD-325901 and docetaxel in human head and neck squamous cell carcinoma
In this study, we determined the effects of the novel PI3K-mTOR inhibitor PF-5212384 (PF-384) on molecular targets and HNSCC growth in preclinical models. PF-384 IC50s of 0.75nM-133nM were found in 12 HNSCC lines by XTT cell density assays and treatment resulted in increased sub-G0 cell death and G0/G1 phase blockade by DNA flow cytometry. PF-384 strongly inhibited direct targets of PI3K-mTOR, aberrant NF-kB transactivation and induced cytokines, but only partially inhibited MEK pathway targets. Transient siRNA knockdown of PIK3CA inhibited NF-kB activity, supporting PI3K-mTOR as an important driver and target for inhibiti...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Mohan, S., Broek, R. J. V., Saleh, A. D., Pierce, M. L., Coupar, J. F., Eytan, D. F., Chen, Z., Waes, C. V. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 5403: Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer
Purpose: The purpose of this study was to investigate the combined antitumor effects of metronomic docetaxel-containing PLGA-PRINT nanoparticles and antiangiogenic mEZH2 siRNA incorporated into chitosan nanoparticles (CH-mEZH2 siRNA). Method: In vivo dose-finding studies and therapeutic experiments with PLGA-PRINT-docetaxel and CH-mEZH2 siRNA were conducted in well-established orthotopic mouse models of ovarian cancer (HeyA8 and SKOV3ip1). Antitumor effects were quantified through mean tumor weight and tumor nodule counts. Tumor tissues from these studies were stained to evaluate the proliferation index (Ki67), apoptosis i...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Gharpure, K. M., Chu, K. S., Bowerman, C., Miyake, T., Pradeep, S., Mangala, L. S., Han, H.-D., Rupaimoole, R., Wu, S. Y., Dalton, H. J., Napier, M. E., Lopez-Berestein, G., DeSimone, J. M., Sood, A. K. Tags: Cancer Chemistry Source Type: research

Abstract 5033: Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell
Conclusions: The findings obtained from the current study suggested that 5-FU and DTX may enhance the T cell-stimulating ability of DCs via down-regulation of PD-L1 and PD-L2 mediated by STAT3 inhibition, and that the combination therapy of DC-based cancer vaccine with these anti-cancer drugs may elicit better anti-tumor immune response than only vaccination. Citation Format: Masato Okamoto, Tomoyuki Tano, Hiroyuki Goda, Yohei Fujita, Koh-ichi Nakashiro, Hiroyuki Hamakawa. Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell. [abst...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Okamoto, M., Tano, T., Goda, H., Fujita, Y., Nakashiro, K.-i., Hamakawa, H. Tags: Immunology Source Type: research

Abstract 731: SRI-28731, a highly potent and selective MAP4K4 (HGK) inhibitor for cancer therapy
MAP4K4, a Ser/Thr kinase, was identified as an important pro-migratory kinase in an siRNA screen, targeting 5,234 human genes for modulators of tumor cell motility. MAP4K4 siRNA potently suppressed cell invasion and migration of multiple cancer cell lines, indicating a broad role in cell motility. There are no drugs in the clinic that are known to specifically target MAP4K4 for cancer therapy. We have successfully developed an orally active, highly effective and selective MAP4K4 inhibitor (SRI-28731) with potent in vitro and in vivo anticancer activity. SRI-28731 is more potent than Paclitaxel (Taxol) against most of the b...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Chang, C.-T., Park, J., Zhou, W., Liu, X., Sato, B., Dinh, D., Furimsky, A., Beviglia, L., Sambucetti, L., Jong, L. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 3310: N-cadherin promotes docetaxel resistance through upregulated TLR4 signaling in castration resistant prostate cancers
In this study, our objective is to determine the role of N-cadherin expression in chemoresistance and whether treatment with monoclonal antibodies restores chemosensitivity. Methods: Tissue microarrays of CRPC and high grade prostate cancer clinical samples were stained for TLR4. N-cadherin positive and negative cell lines were evaluated for sensitivity against docetaxel. N-cadherin and TLR4 were ectopically expressed in N-cadherin negative prostate cancer cells (LNCaP, VCaP). Docetaxel resistant cell lines (LNCaP-DocR and VCaP-DocR) were established through prolonged exposure to 10-20uM Docetaxel. For in vitro experiments...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Shimomura, T., Kono, E., Tran, C. P., Yamashiro, J., Lin, S., Lee, S. H.-K., Wainberg, Z. A., Reiter, R. E. Tags: Molecular and Cellular Biology Source Type: research

EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
In this study, we explored the mechanism of EGFR-mediated docetaxel resistance in PC. A series of stable docetaxel-resistant PC/DX sublines were established at our laboratory. The docetaxel IC50s of PC3 and PC/DX25 cells were 0.01 and 1.33 μM, respectively. Cellular resistance to docetaxel was significantly associated with increased EGFR and EGFR activation in PC/DX25. There was a dose-dependent increase in EGFR expression associated with the magnitude of docetaxel resistance. Expression of EGFR in PC/DX25 was higher than that in PC3, RWPE-1 and LNCaP cells. Similar results were also found in human PC tissues by immunohi...
Source: Archives of Toxicology - June 3, 2014 Category: Toxicology Authors: Hour TC, Chung SD, Kang WY, Lin YC, Chuang SJ, Huang AM, Wu WJ, Huang SP, Huang CY, Pu YS Tags: Arch Toxicol Source Type: research

TR4 Promotes Chemoresistance in PCa Stem Cells Gene Regulation
Prostate cancer (PCa) stem/progenitor cells are known to have higher chemoresistance than non-stem/progenitor cells, but the underlying molecular mechanism remains unclear. We found the expression of testicular nuclear receptor 4 (TR4) is significantly higher in PCa CD133+ stem/progenitor cells compared with CD133− non-stem/progenitor cells. Knockdown of TR4 levels in the established PCa stem/progenitor cells and the CD133+ population of the C4-2 PCa cell line with lentiviral TR4 siRNA led to increased drug sensitivity to the two commonly used chemotherapeutic drugs, docetaxel and etoposide, judging from significantly re...
Source: Journal of Biological Chemistry - June 7, 2013 Category: Chemistry Authors: Yang, D.-R., Ding, X.-F., Luo, J., Shan, Y.-X., Wang, R., Lin, S.-J., Li, G., Huang, C.-K., Zhu, J., Chen, Y., Lee, S. O., Chang, C. Tags: Cell Biology Source Type: research

Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia
Conclusions: Interrupting Vav3 signaling enhances docetaxel-induced apoptosis in LNCaP cells under chronic hypoxia by inhibiting the PI3K/Akt, ERK, and AR signaling pathways. Therapy targeting Vav3 in combination with docetaxel may have practical implications for managing castration-resistant prostate cancer.
Source: Molecular Cancer - April 8, 2013 Category: Cancer & Oncology Authors: Takeo NomuraMutsushi YamasakiKenichi HiraiToru InoueRyuta SatoKeiko MatsuuraMasatsugu MoriyamaFuminori SatoHiromitsu Mimata Source Type: research

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
CONCLUSIONS: These findings indicate that MSV/EphA2 merits further development as a novel therapeutic agent for ovarian cancer. PMID: 23386691 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 5, 2013 Category: Cancer & Oncology Authors: Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang GD, Guo X, Bao L, Guoting Q, Deng X, Li Q, Erm D, Sakamoto JH, Liu X, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G Tags: Clin Cancer Res Source Type: research

Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma
Highlights: ► HORMAD1 is a cancer/testis antigen expressed exclusively in germ cells during normal development. ► HORMAD1 is expressed in a substantial portion of human epithelial ovarian cancers. ► HORMAD1 down-regulation affected tumor growth in mouse models of human ovarian cancer.Abstract: The present study was undertaken to determine the expression and biological significance of HORMAD1 in human epithelial ovarian carcinoma. We found that a substantial proportion of human epithelial ovarian cancers expressed HORMAD1. In vitro, HORMAD1 siRNA enhanced docetaxel induced apoptosis and substantially reduced the invas...
Source: Cancer Letters - July 30, 2012 Category: Cancer & Oncology Authors: Mian M.K. Shahzad, Yong-Hyun Shin, Koji Matsuo, Chunhua Lu, Masato Nishimura, De-Yo Shen, Yu Kang, Wei Hu, Edna M. Mora, Cristian Rodriguez-Aguayo, Arvinder Kapur, Justin Bottsford-Miller, Gabriel Lopez-Berestein, Aleksandar Rajkovic, Anil K. Sood Tags: Mini-reviews Source Type: research

The Role of Hypoxia-Inducible Factor-1α and -2α in Androgen Insensitive Prostate Cancer Cells
Conclusions: Our results demonstrate that HIF-1α and -2α are important for cell proliferation and invasion ability in prostate cancer. Together, our results indicate that combinations of target agents with HIF knockdown may represent a promising strategy for the treatment of prostate cancer.
Source: Urologic Oncology: Seminars and Original Investigations - April 27, 2012 Category: Urology & Nephrology Authors: Chang Wook Jeong, Cheol Yong Yoon, Seong Jin Jeong, Sung Kyu Hong, Seok-Soo Byun, Cheol Kwak, Sang Eun Lee Tags: Clinical - Prostate Source Type: research